MedPAC chair defends Medicare Advantage overpayment analysis at insurer lobby event

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 23 Sept, 13:41 UTC

Amid growing public debate over how best to analyze spending in MA versus traditional Medicare, Dr. Amol Navathe, the leader of the group behind the most-cited estimate, stepped into the lion’s den to support its work.

science

Sources

• T2MedPAC chair defends Medicare Advantage overpayment analysis at insurer lobby eventBioPharma Dive / Healthcare Dive / MedTech Dive23 Sept, 13:41